Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 3INTERVENTIONAL

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

The Purpose of This Clinical Study is to Prove That the Test Drug (AJU-S56 5%) is Superior to the Control Drug After 24 Weeks of Administration to Patients Who Have Moderate or Severe Dry Eye Syndrome

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.

Who May Be Eligible (Plain English)

Who May Qualify: - Male and Female who over 19 years old - Moderate to Severe Dry Eye Disease Patients - Must meet all criteria listed below at least in one eye or both eyes. 1. TCSS (National eye institute (NEI) scale)≥ 4 2. Ocular discomfort score (ODS) ≥ 3 3. Schirmer test(without anesthesia) ≤ 10mm in 5 mins 4. Tear break-up time ≤ 6 secs - Written willing to sign a consent form to participate in the trial Who Should NOT Join This Trial: - Those who have clinically significant eye disease not related to dry eye syndrome - Those who have worn contact lenses before 1week Screening visit or have to wear contact lenses or need to wear contact lenses during study period - Those who have medical history with intraocular surgery 12months before screening visit - Use of corticosteroid, beta blocker and anticholinergic agent within 4 weeks - Participation in other studies within 4weeks of screening visit Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Male and Female who over 19 years old * Moderate to Severe Dry Eye Disease Patients * Must meet all criteria listed below at least in one eye or both eyes. 1. TCSS (National eye institute (NEI) scale)≥ 4 2. Ocular discomfort score (ODS) ≥ 3 3. Schirmer test(without anesthesia) ≤ 10mm in 5 mins 4. Tear break-up time ≤ 6 secs * Written informed consent to participate in the trial Exclusion Criteria: * Those who have clinically significant eye disease not related to dry eye syndrome * Those who have worn contact lenses before 1week Screening visit or have to wear contact lenses or need to wear contact lenses during study period * Those who have medical history with intraocular surgery 12months before screening visit * Use of corticosteroid, beta blocker and anticholinergic agent within 4 weeks * Participation in other studies within 4weeks of screening visit

Treatments Being Tested

DRUG

AJU-S56 5%

After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

DRUG

Placebo Group(Vehicle)

After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

Locations (1)

AJU Pharm Co., Ltd.
Seoul, South Korea